PSMA-PET Reliable for Prostate Cancer Detection in Radical Prostatectomy
A recent study toward more precise prostate cancer detection found the potential of PSMA-PET (prostate-specific membrane antigen-positron emission tomography) in biopsy-free radical prostatectomy. According to the study, this procedure relies on prior biopsies, but the PSMA-PET approach could revolutionize this norm. The findings of the research were published in the Journal of Urology.
This retrospective study analyzed the intersection of PSMA-PET, benign prostatic hyperplasia (BPH), and prostate cancer. The major concern was the expression of PSMA in BPH tissue, which could lead to false positives. The study, a first in its kind, unveiled a BPH-related false-positive rate of 30% in PSMA-PET's detection of prostate cancer.
The research also found the significance of the maximum standardized uptake value (SUVmax) and the Prostate Imaging Reporting & Data System (PI-RADS) in steering biopsy-free radical prostatectomy. The SUVmax emerged as a critical parameter, effectively excluding BPH and low-grade prostate cancer patients. An optimal SUVmax cutoff value of 15 exhibited 100% specificity but with a sensitivity of 41%.
The stringent PET scores and PI-RADS criteria (both ≥4) showed promising results in diagnosing clinically significant prostate cancer, achieving a sensitivity of 49% and 100% specificity.
These findings mark a significant step toward biopsy-free radical prostatectomy while caution is warranted. The study underscores the need for further research, especially in large-scale clinical trials, to solidify the efficacy and safety of PSMA-PET in managing prostate cancer. As discussions on the broader implications of this breakthrough unfold, the patients are reminded to prioritize evidence-based, standard-of-care treatments until a clearer consensus emerges.
Reference:
Tang, W., Tang, Y., Qi, L., Zhang, Y., Tang, G., Gao, X., Hu, S., & Cai, Y. (2023). Benign Prostatic Hyperplasia–Related False-Positive of Prostate-Specific Membrane Antigen–Positron Emission Tomography in the Diagnosis of Prostate Cancer: The Achilles’ Heel of Biopsy-Free Radical Prostatectomy? In Journal of Urology (Vol. 210, Issue 6, pp. 845–855). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1097/ju.0000000000003680
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.